Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
View/ Open
Author
Gillessen, S.
Omlin, A.
Attard, G.
de Bono, J. S.
Efstathiou, E.
Fizazi, K.
Halabi, S.
Nelson, P. S.
Sartor, O.
Smith, M. R.
Soule, H. R.
Akaza, H.
Beer, T. M.
Beltran, H.
Chinnaiyan, A. M.
Daugaard, G.
Davis, I. D.
De Santis, M.
Drake, C. G.
Eeles, R. A.
Fanti, S.
Gleave, M. E.
Heidenreich, A.
Hussain, M.
James, N. D.
Lecouvet, F. E.
Logothetis, C. J.
Mastris, K.
Nilsson, S.
Oh, W. K.
Olmos, D.
Padhani, A. R.
Parker, C.
Rubin, M. A.
Schalken, J. A.
Scher, H. I.
Sella, A.
Shore, N. D.
Small, E. J.
Sternberg, C. N.
Suzuki, H.
Sweeney, C. J.
Tannock, I. F.
Tombal, B.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1093/annonc/mdv257Metadata
Show full item recordCitation
Gillessen, S., A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, et al. 2015. “Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.” Annals of Oncology 26 (8): 1589-1604. doi:10.1093/annonc/mdv257. http://dx.doi.org/10.1093/annonc/mdv257.Abstract
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511225/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820850
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)
Related items
Showing items related by title, author, creator and subject.
-
The High Prevalence of Undiagnosed Prostate Cancer at Autopsy: Implications for Epidemiology and Treatment of Prostate Cancer in the Prostate-Specific Antigen-Era
Jahn, Jaquelyn; Giovannucci, Edward; Stampfer, Meir (Wiley, 2015)Widespread prostate-specific antigen (PSA) screening detects many cancers that would have otherwise gone undiagnosed. To estimate the prevalence of unsuspected prostate cancer, we reviewed 19 studies of prostate cancer ... -
Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality
Mirabeau-Beale, Kristina; Chen, Ming-Hui; D'Amico, Anthony V. (Hindawi Publishing Corporation, 2014)Purpose. We evaluated the impact a prior cancer diagnosis had on the risk of prostate-cancer-specific mortality (PCSM) and all-cause mortality (ACM) in men with PC. Methods:. Using the SEER data registry, 166,104 men (median ... -
Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium
Shui, Irene M.; Lindström, Sara; Kibel, Adam S.; Berndt, Sonja I.; Campa, Daniele; Gerke, Travis; Penney, Kathryn L.; Albanes, Demetrius; Berg, Christine; Bueno-de-Mesquita, H. Bas; Chanock, Stephen; Crawford, E. David; Diver, W. Ryan; Gapstur, Susan M.; Gaziano, J. Michael; Giles, Graham G.; Henderson, Brian; Hoover, Robert; Johansson, Mattias; Marchand, Loic Le; Ma, Jing; Navarro, Carmen; Overvad, Kim; Schumacher, Fredrick R.; Severi, Gianluca; Siddiq, Afshan; Stampfer, Meir; Stevens, Victoria L.; Travis, Ruth C.; Trichopoulos, Dimitrios; Vineis, Paolo; Mucci, Lorelei A.; Yeager, Meredith; Giovannucci, Edward; Kraft, Peter (Elsevier, 2014)Background: Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk ...